期刊
INTERNATIONAL JOURNAL OF NANOMEDICINE
卷 13, 期 -, 页码 1215-1224出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJN.S149375
关键词
osteoarthritis; nanosome; diagnosis; OA score; destabilization of the medial meniscus; matrix metalloproteinases; monoclonal anti-type II collagen antibody
资金
- Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI17C2191]
- Department of Veterans Affairs
- NIH [AR060408]
- UTHSC (KAH)
- Arthritis Foundation
- William and Ella Owens Medical Research Foundation
Background: Early stage osteoarthritis (OA) is clinically asymptomatic due to the avascular and the aneural nature of the cartilage tissue. Nevertheless, early detection of cartilage tissue is critical in order to impede the progression of OA. Hence, in order to develop effective preventive therapy for OA, diagnosis in the early stages is necessary. Methods: To achieve this goal, we have developed targeted, fluorescent nanosomes conjugated with monoclonal anti-type II collagen antibodies (MabCII) for diagnosis of early OA. The MabCII-coated nanosomes (targeted-nanosomes) bind to the damaged cartilage explants in vitro and in vivo in an OA mouse model that mimics early stage OA. The OA mouse model was induced by destabilization of the medial meniscus (DMM) in 9-10 weeks old C57Bl/6 mice. Results: The targeted-nanosomes enhanced the binding specificity to the cartilage tissue according to the severity of damage. Conclusion: We show that MabCII-nanosomes can precisely detect early stage OA in the DMM mouse model. Thus, MabCII-nanosomes have the potential to be used as a non-invasive method for diagnosing the early osteoarthritic lesions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据